CATT Editorials and Commentary

  1. Martin DF, Maguire MG, Fine SL. Identifying and eliminating the roadblocks to comparative-effectiveness research. N Engl J Med 2010; 363:105-7. Epub 2010 Jun 2.
  2. Martin DF, Maguire MG, Fine SL. Bevacizumab: not as good with more adverse reactions? Response. Clinical and Experimental Ophthalmology 2011; 39:718-720.
  3. Martin DF, Maguire MG, Fine SL. Ranibizumab and bevacizumab for AMD. Authors reply. N Engl J Med 2011; 365:2237.
  4. Grunwald JE. Risk of geographic atrophy in Comparison of Age-related Macular Degeneration Treatments Trials. Authors reply. Ophthalmology. Epub 2014 Mar 7.
  5. Hagstrom S, Ying G-S, Maguire MG, Martin D. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Authors reply. Ophthalmology 2014; 121:e44-5. Epub 2014 May 6.
  6. Martin DF, Fine SL, Maguire MG. Cost-Related Motivations for Research. Letter to the Editor. JAMA 2014; 312:847.
  7. Hagstrom S, Ying GS, Pauer GJ, Huang J, Maguire MG, Martin DF. Endothelial PAS domain-containing protein 1 (EPAS1) gene polymorphisms and response to anti-VEGF therapy in the Comparison of AMD Treatments Trials (CATT). Letter to the Editor. Ophthalmology 2014; 121:1663-4. Epub 2014 May 9.
  8. Ying G-S, Maguire MG. Comparative effectiveness of bevacizumab and ranibizumab in the Comparison of Age-Related Macular Degeneration Treatments Trials. Authors reply. JAMA Ophthalmology. Epub 2015 Mar 26.
  9. Jaffe GJ, the CATT Research Group. Macular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trials. Authors reply. Ophthalmology 2017; 124:e19.
  10. Maguire MG, the CATT Research Group. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 2017; 124:e33.